Alaunos Therapeutics, Inc. (TCRT)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 17, 2025

$1.80

P/E Ratio

N/A

Market Cap

$2.88M

Jan 30, 2024Mar 8, 2024Apr 10, 2024May 20, 2024Jun 21, 2024Jul 24, 2024Aug 27, 2024Oct 2, 2024Nov 4, 2024Dec 5, 2024Jan 20, 2025$0.00$10.00
  • PVT
Description

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.

Metrics

Overview

  • HQHouston, TX
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerTCRT
  • Price$1.8+4.05%

Trading Information

  • Market cap$2.88M
  • Float86.25%
  • Average Daily Volume (1m)26,815
  • Average Daily Volume (3m)24,810
  • EPS-$7.36

Company

  • Revenue$0.01M
  • Rev growth (1yr)N/A
  • Net income-$1.13M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$1.15M
  • EV$3.47M
  • EV/Revenue578.84
  • P/EN/A
  • P/S480.38
  • P/B1.06
Documents